Also known as Robinul
Glycopyrronium bromide is a medication of the muscarinic anticholinergic group. It does not cross the blood–brain barrier and consequently has no to few central effects. A synthetic quaternary amine, it is available in oral and intravenous (i.v.) forms. It was developed by Sosei and licensed to Novartis in 2005. The cation, which is the active moiety, is also known as glycopyrrolate.Source: Wikipedia
Estimated Total Cost: $74.28 for an average of 28 days supply
Patients are most commonly prescribed glycopyrrolate to treat cerebral palsy, gallstone, upper abdominal pain, and cholecystitis.